Development and validation of a liquid chromatography-tandem mass spectrometry method for the determination of febuxostat in human plasma

被引:33
作者
Wang, Haidong [1 ,2 ]
Deng, Pan [1 ]
Chen, Xiaoyan [1 ]
Guo, Lixia [1 ]
Zhong, Dafang [1 ,2 ]
机构
[1] Chinese Acad Sci, Shanghai Inst Mat Med, Shanghai 201203, Peoples R China
[2] Zhejiang Univ Technol, Hangzhou 310014, Zhejiang, Peoples R China
关键词
febuxostat; liquid chromatography with tandem mass spectrometry detection; pharmacokinetic; SELECTIVE INHIBITOR; NON-PURINE; XANTHINE-OXIDASE; PHARMACODYNAMICS; PHARMACOKINETICS; HYPERURICEMIA; MANAGEMENT; SAFETY;
D O I
10.1002/bmc.2744
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
A rapid and sensitive analytical method based on liquid chromatography coupled to tandem mass spectrometry detection with positive ion electrospray ionization was developed for the determination of febuxostat in human plasma using d7-febuxostat as the internal standard (IS). A simple protein precipitation was performed using acetonitrile. The analyte and IS were subjected to chromatographic analysis on a Capcell PAK C18 column (4.6 x 100 mm, 5 mu m) using acetonitrile5 mm ammonium acetateformic acid (85:15:0.015, v/v/v) as the mobile phase at a flow rate of 0.6 mL/min. An Agilent 6460 electrospray tandem mass spectrometer was operated in the multiple reaction monitoring mode. The precursor-to-product ion transitions m/z 317???m/z 261 (febuxsotat) and m/z 324???m/z (261?+?262) (d7-febuxostat, IS) were used for quantitation. The results were linear over the studied range (10.05000 ng/mL), and the total analysis time for each chromatograph was 3 min. The intra- and inter-day precisions were less than 7.9 and 7.2%, respectively, and the accuracy was within +/- 4.2%. No evidence of analyte instability in human plasma was observed storage at -20 degrees C for 31 days. This method was successfully applied in the determination of febuxostat concentrations in plasma samples from healthy Chinese volunteers. Copyright (c) 2012 John Wiley & Sons, Ltd.
引用
收藏
页码:34 / 38
页数:5
相关论文
共 11 条
[1]   Management of hyperuricemia with rasburicase review [J].
de Bont, JM ;
Pieters, R .
NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS, 2004, 23 (8-9) :1431-1440
[2]   Febuxostat: A Selective Xanthine-Oxidase/Xanthine-Dehydrogenase Inhibitor for the Management of Hyperuricemia in Adults With Gout [J].
Ernst, Michael E. ;
Fravel, Michelle A. .
CLINICAL THERAPEUTICS, 2009, 31 (11) :2503-2518
[3]   The effect of mild and moderate hepatic impairment on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase [J].
Khosravan, R ;
Grabowski, BA ;
Mayer, MD ;
Wu, JT ;
Joseph-Ridge, N ;
Vernillet, L .
JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 46 (01) :88-102
[4]   Effect of food or antacid on pharmacokinetics and pharmacodynamics of febuxostat in healthy subjects [J].
Khosravan, Reza ;
Grabowski, Brian ;
Wu, Jing-Tao ;
Joseph-Ridge, Nancy ;
Vernillet, Laurent .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2008, 65 (03) :355-363
[5]   Pharmacokinetics, pharmacodynamics and safety of febuxostat, a non-purine selective inhibitor of xanthine oxidase, in a dose escalation study in healthy subjects [J].
Khosravan, Reza ;
Grabowski, Brian A. ;
Wu, Jing-Tao ;
Joseph-Ridge, Nancy ;
Vernillet, Laurent .
CLINICAL PHARMACOKINETICS, 2006, 45 (08) :821-841
[6]   Pharmacokinetic interactions of concomitant administration of febuxostat and NSAIDs [J].
Khosravan, Reza ;
Wu, Jing-Tao ;
Joseph-Ridge, Nancy ;
Vernillet, Laurent .
JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 46 (08) :855-866
[7]   Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS [J].
Matuszewski, BK ;
Constanzer, ML ;
Chavez-Eng, CM .
ANALYTICAL CHEMISTRY, 2003, 75 (13) :3019-3030
[8]   Febuxostat: a non-purine, selective inhibitor of xanthine oxidase for the management of hyperuricaemia in patients with gout [J].
Schumacher, HR .
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2005, 14 (07) :893-903
[9]   Selectivity of febuxostat, a novel non-purine inhibitor of xanthine oxidase/xanthine dehydrogenase [J].
Takano, Y ;
Hase-Aoki, K ;
Horiuchi, H ;
Zhao, L ;
Kasahara, Y ;
Kondo, S ;
Becker, MA .
LIFE SCIENCES, 2005, 76 (16) :1835-1847
[10]  
United States Food and Drug Administration (FDA), 2008, GUID IND SAF TEST DR